Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-521P is a **processed pseudogene** derived from the highly conserved U6 small nuclear RNA (snRNA) gene, **not a functional therapeutic target or protein-coding gene**[5][3][2][4]. RNU6-521P is classified as a **processed pseudogene** of the U6 small nuclear RNA (snRNA) family[5][3][2]. U6 snRNAs are essential non-coding RNAs in eukaryotes, forming a key component of the **spliceosome** used to remove introns from pre-mRNA during gene expression[1][3]. However, **RNU6-521P itself is a non-functional, non-coding RNA sequence**: due to mutations and the lack of crucial regulatory elements, it does not produce a mature, functional U6 RNA or participate in the spliceosome[5][3][2]. While most pseudogenes are regarded as “functionless relics” of evolutionary history, emerging studies demonstrate that some pseudogenes can be transcribed and may act in regulatory roles, such as **sponging microRNAs or RNA-binding proteins**, or interfering with parental gene expression[2][4]. There is no evidence that RNU6-521P encodes a protein, interacts with drugs, or functions as a therapeutic target[5][3]. **Key notes:** - **RNU6-521P** is not a gene product or receptor, but a **pseudogene copy** of the U6 snRNA gene[5][3][2]. - There are hundreds of such pseudogenes across the human genome[3][4], often arising by **retrotransposition**[2]. - Its main importance is in genomics for annotation and, potentially, understanding the evolution and regulation of snRNA genes. This entry should generally be excluded from target lists focused on therapeutic intervention, as it is not a protein, enzyme, receptor, or other actionable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 521, pseudogene (RNU6-521P).